Poolbeg Pharma has announced that the European Patent Office has granted its European Immunomodulator II patent application for POLB 001, a treatment targeting severe influenza.
The clinical-stage biopharmaceutical company, which focuses on advancing cancer immunotherapy, said the patent covers the use of POLB 001, a selective p38 MAP kinase inhibitor.
The treatment has shown strong potential across several disease areas, including the prevention and treatment of cancer immunotherapy-induced Cytokine Release Syndrome (CRS) – a market estimated to be worth over US$10 billion – as well as severe influenza.
Poolbeg is actively expanding its global intellectual property portfolio. The company said the new patent grant further strengthens its position, enhancing the value and appeal of POLB 001 to potential partners.
Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said: “This patent grant from the European Patent Office highlights the strong progress we continue to make in developing and strengthening our IP portfolio for POLB 001 across multiple disease indications. This further enhances the value and attractiveness of POLB 001 for potential partners.”
The company’s IP strategy includes patents covering the use of p38 MAPK inhibitors in patients with severe influenza and for the prevention and treatment of CRS caused by cancer immunotherapy. POLB 001 is currently in development and holds the potential to address significant unmet needs in global healthcare.
Poolbeg’s announcement marks another step forward in its mission to transform the cancer immunotherapy landscape and deliver innovative treatments for serious conditions.
